High glucose and homocysteine synergistically affect the metalloproteinases–tissue inhibitors of metalloproteinases pattern, but not TGFB expression, in human fibroblasts
- 1 August 2006
- journal article
- research article
- Published by Springer Nature in Diabetologia
- Vol. 49 (10) , 2499-2506
Abstract
Aims/hypothesis Atherosclerosis is particularly aggressive in patients with diabetes. Hyperhomocysteinaemia causes oxidative stress and cytokine secretion: its atherogenic effect is mediated by an enhanced inflammatory response. Matrix metalloproteinases (MMPs) regulate extracellular matrix degradation and remodelling, and contribute to the vulnerability of the atherosclerotic lesion. Fibroblasts contribute to collagen biosynthesis and participate in plaque remodelling via expression and release of MMP2 and MMP9. To explore the role of hyperhomocysteinaemia in cellular pathways involved in plaque growth and stability in diabetic patients, we studied the effect of hyperhomocysteinaemia in human fibroblasts grown in the presence of normal or high glucose concentrations. Materials and methods In fibroblasts of five normal subjects, grown at 5.5 or 22 mmol/l glucose and treated with homocysteine, we determined: (1) MMP2, MMP9 and tissue inhibitor of metalloproteinases (TIMP)-1 (an MMP inhibitor) production by western blot analysis; (2) their activity by zymography; (3) TGFB1 expression by real-time PCR; and (4) TGFB, fibronectin and IL6 release by ELISA. Results Hyperhomocysteinaemia increased the production and enzymatic activity of MMP2 and MMP9, the effect being more pronounced in high glucose. Conversely, TIMP1 production was reduced by hyperhomocysteinaemia in both conditions, especially in high glucose. Hyperhomocysteinaemia also stimulated IL6 release, at least in part through nuclear factor-κB activation. TGFB1 expression was not affected by hyperhomocysteinaemia either in normal or in high glucose. Conclusions/interpretation Homocysteine upregulates the MMP–TIMP pathway and IL6 release, the effect being stronger in the presence of high glucose. These actions of homocysteine may contribute to the increased atherogenesis observed in diabetic patients with poor metabolic control.Keywords
This publication has 36 references indexed in Scilit:
- Reduced serum homocysteine levels in type 2 diabetesNutrition, Metabolism and Cardiovascular Diseases, 2005
- Vitamin C or Vitamin B6 supplementation prevent the oxidative stress and decrease of prostacyclin generation in homocysteinemic ratsThe International Journal of Biochemistry & Cell Biology, 2004
- Homocysteine induces metalloproteinase and shedding of β‐1 integrin in microvessel endothelial cellsJournal of Cellular Biochemistry, 2004
- Prognostic value of plasma interleukin-6 concentrations and the −174 G > C and −572 G > C promoter polymorphisms of the interleukin-6 gene in patients with acute myocardial infarction treated with thrombolysisAtherosclerosis, 2004
- Relationship of homocysteine to markers of platelet and endothelial activation in ‘high risk’ hypertensives: a substudy of the Anglo-Scandinavian Cardiac Outcomes TrialInternational Journal of Cardiology, 2004
- Homocysteine Mediated Expression and Secretion of Monocyte Chemoattractant Protein-1 and Interleukin-8 in Human MonocytesCirculation Research, 2003
- Homocysteine enhances TIMP-1 expression and cell proliferation associated with NADH oxidase in rat mesangial cellsKidney International, 2003
- α-Tocopherol Induces Expression of Connective Tissue Growth Factor and Antagonizes Tumor Necrosis Factor-α–Mediated Downregulation in Human Smooth Muscle CellsCirculation Research, 2003
- Elevated levels of homocysteine increase IL-6 production in monocytic Mono Mac 6 cellsBlood Coagulation & Fibrinolysis, 2000
- Hyperhomocysteinemia Is Associated With an Increased Risk of Cardiovascular Disease, Especially in Non–Insulin-Dependent Diabetes MellitusArteriosclerosis, Thrombosis, and Vascular Biology, 1998